It can be hard to keep track of new clinical trial opportunities opening across the United States, especially during the current public health crisis created by the coronavirus (COVID-19). However, there are many clinical trials still actively enrolling patients, and this report provides a summary of the studies that have recently opened or started for primary brain tumor patients*. To learn more about each trial, and to contact the party responsible for enrolling patients, just follow the hyperlink.**
- A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma
- Brief Description: This phase III trial investigates the best dose of vinblastine in combination with selumetinib and the benefit of adding vinblastine to selumetinib compared to selumetinib alone in treating children and young adults with a low-grade glioma that has come back after prior treatment (recurrent) or does not respond to therapy (progressive).
- A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG) (KONQUER)
- Brief Description: This phase I trial will evaluate the safety of BXQ-350 and determine the maximum tolerated dose (MTD) in children with newly diagnosed DIPG or DMG. All patients will receive BXQ-350 by intravenous (IV) infusion and radiation therapy. The study is divided into two parts: part 1 will enroll patients at increasing dose levels of BXQ-350 in order to determine the MTD; part 2 will enroll patients requiring a biopsy in order to assess BXQ-350 concentrations in the biopsied tumor.
- Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma (JAZZ)
- Brief Description: This phase II trial studies the side effects of solriamfetol in improving sleep in patients with grade II-IV glioma. Solriamfetol is a wakefulness-promoting drug. Giving solriamfetol may improve sleep, memory, fatigue, mood, or quality of life in patients with gliomas.
- Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
- Brief Description: This phase II trial studies the effect of avapritinib in treating malignant solid tumors that have a genetic change (mutation) in CKIT or PDGFRA and have spread to nearby tissue or lymph nodes (locally advanced) or other places in the body (metastatic), including central nervous system tumors.
- A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors
- Brief Description: In this phase II trial, the researchers want to learn about regorafenib taken together with nivolumab in a small number of participants with different types of tumors, including grade III anaplastic astrocytoma and grade IV glioblastoma.
- A Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
- Brief Description: This first-in-human phase I trial will assess safety, tolerability, and preliminary activity of PF-07284890 as a single agent and in combination with binimetinib in participants with BRAF V600-mutated advanced solid tumor malignancies including brain tumors.
- Immersive Virtual Reality (VR) at the Time of Clinical Evaluation to Improve Psychological Distress and Anxiety in Primary Brain Tumor (PBT) Patients
- Brief Description: This phase II trial will assess the feasibility of using virtual reality technology to help relaxation in primary brain tumor patients experiencing distress and anxiety.
- Safety Study of Pritumumab in Brain Cancer
- Brief Description: This is an open-label, phase II, outpatient, dose-escalation study of pritumumab in patients with brain cancer who have failed prior therapy and have no other available options. The trial will seek to determine the safety and/or tolerability and the recommended phase II dose of escalating, intravenously (IV) administered pritumumab.
- DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
- Brief Description: This phase II trial will assess difluoromethylornithine (DFMO) as a potential maintenance therapy for molecular high-risk and relapsed/refractory medulloblastoma.
- A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
- Brief Description:RSC-101 is a phase Ia/Ib clinical trial of RSC-1255 in adults studying participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have a disease that has progressed after standard therapy or have previously failed other therapies. Glioblastoma patients are eligible. The study has two phases. The purpose of phase Ia (Dose Escalation) is to confirm the appropriate treatment dose, and the purpose of phase Ib (Dose Expansion) is to characterize the safety and efficacy of RSC-1255.
*For a more comprehensive list of ALL open brain tumor clinical trials, visit the NBTS Clinical Trial Finder, where you can search potential opportunities for enrollment based on criteria important and specific to you.
**For additional navigation support, you can access NBTS’s Personalized Support and Navigation program by emailing firstname.lastname@example.org. Our patient navigator, Mary Lovely, PhD, RN, CNRN, has more than 30 years of experience working closely with brain tumor patients and families as a neurological nurse, clinical nurse specialist, and research nurse.
> Learn more